Novartis has reported positive results from clinical trial programs involving indacaterol/glycopyrronium (QVA149) and glycopyrronium/bromide (NVA237).
The company is submitting New Drug Applications to the US Food and Drug Administration for the drugs as long-term treatments against chronic obstructive pulmonary disease.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management